ASH Annual Meeting & Exposition: Lymphoma | Conference

Michael R. Bishop, MD, discussed how he thinks the results from phase 3 BELINDA study may impact the treatment landscape in B-cell lymphomas moving forward.

Michael R. Bishop, MD, highlighted the population of patients with relapsed/refractory B-cell non-Hodgkin lymphoma who were enrolled on the phase 3 BELINDA study and treated with tisagenlecleucel.

Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.

Sattva S. Neelapu, MD, spoke about continuing to look at results from the ZUMA-5 trial to determine if axicabtagene ciloleucel can cure patients with relapsed or refractory indolent non-Hodgkin lymphoma

Patients with previously untreated diffuse large B-cell lymphoma experienced promising responses after being treated with tafasitamab-cxix and lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristin, and prednisone.

Patients with high-risk large B-cell lymphoma saw durable responses when treated with axicabtagene ciloleucel.

A 27% reduction in the risk of progression or death was noted when polatuzumab vedotin was added on R-CHP vs R-CHOP for patients with intermediate- or high-risk diffuse large B-cell lymphoma who received treatment in the first line.

A positive overall response rate was achieved when patients with relapsed/refractory peripheral T-cell lymphoma were treated with duvelisib plus romidespin.

Patients with large B-cell lymphoma who were previously excluded from investigations experienced increased efficacy with the use of axicabtagene ciloleucel.

Glofitamab monotherapy or in combination with obinutuzumab led to strong response rates for patients with multiple relapsed or refractory follicular lymphoma.